Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design.
Nanfack AJ, Takou D, Fokam J, Salpini R, Santoro MM, Cappelli G, Baane M, Tetang SM, Eberle J, Gürtler L, Ceccherini-Silberstein F, Torimiro JN, Colizzi V, Perno CF, Ndjolo A. Nanfack AJ, et al. Among authors: perno cf. Curr HIV Res. 2016 Dec 29. Online ahead of print. Curr HIV Res. 2016. PMID: 28034359
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Santoro MM, et al. Among authors: perno cf. New Microbiol. 2006 Apr;29(2):89-100. New Microbiol. 2006. PMID: 16841549
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients.
Alcaro S, Artese A, Ceccherini-Silberstein F, Chiarella V, Dimonte S, Ortuso F, Perno CF. Alcaro S, et al. Among authors: perno cf. Curr Med Chem. 2010;17(4):290-308. doi: 10.2174/092986710790192695. Curr Med Chem. 2010. PMID: 20015046 Review.
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.
Zaccarelli M, Antinori A, Cozzi-Lepri A, Mussini C, Palamara G, Santoro MM, Spagnuolo V, Monforte Ad, Perno CF, Ceccherini-Silberstein F. Zaccarelli M, et al. Among authors: perno cf. J Acquir Immune Defic Syndr. 2010 Jan;53(1):150-1. doi: 10.1097/QAI.0b013e3181c428b4. J Acquir Immune Defic Syndr. 2010. PMID: 20035165 No abstract available.
Resistance to novel drug classes.
Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Marcelin AG, et al. Among authors: perno cf. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Curr Opin HIV AIDS. 2009. PMID: 20048722 Review.
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF. Svicher V, et al. Among authors: perno cf. J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f. J Acquir Immune Defic Syndr. 2010. PMID: 20739898
737 results